Northern Trust Corp reduced its position in shares of Grifols, S.A. (NASDAQ:GRFS) by 0.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 486,733 shares of the biotechnology company’s stock after selling 2,296 shares during the period. Northern Trust Corp’s holdings in Grifols, were worth $10,285,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Comerica Bank increased its stake in Grifols, by 1.3% during the 2nd quarter. Comerica Bank now owns 19,062 shares of the biotechnology company’s stock worth $389,000 after buying an additional 245 shares in the last quarter. Neuberger Berman Group LLC increased its stake in Grifols, by 0.7% during the 2nd quarter. Neuberger Berman Group LLC now owns 47,530 shares of the biotechnology company’s stock worth $1,004,000 after buying an additional 327 shares in the last quarter. Bank of Montreal Can increased its stake in Grifols, by 0.7% during the 2nd quarter. Bank of Montreal Can now owns 70,092 shares of the biotechnology company’s stock worth $1,480,000 after buying an additional 457 shares in the last quarter. Wetherby Asset Management Inc. increased its stake in Grifols, by 3.0% during the 2nd quarter. Wetherby Asset Management Inc. now owns 18,731 shares of the biotechnology company’s stock worth $396,000 after buying an additional 544 shares in the last quarter. Finally, Keybank National Association OH increased its stake in Grifols, by 2.7% during the 2nd quarter. Keybank National Association OH now owns 43,110 shares of the biotechnology company’s stock worth $911,000 after buying an additional 1,124 shares in the last quarter. Institutional investors own 21.84% of the company’s stock.

Shares of Grifols, S.A. (NASDAQ GRFS) opened at $23.58 on Tuesday. The company has a current ratio of 3.17, a quick ratio of 1.39 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $16,312.64, a P/E ratio of 22.33, a price-to-earnings-growth ratio of 1.75 and a beta of 1.07. Grifols, S.A. has a 52 week low of $14.33 and a 52 week high of $24.20.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/northern-trust-corp-cuts-holdings-in-grifols-s-a-grfs/1684640.html.

Several equities research analysts have commented on GRFS shares. Citigroup Inc. started coverage on Grifols, in a research note on Tuesday, October 31st. They set a “buy” rating for the company. Zacks Investment Research lowered Grifols, from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, BidaskClub lowered Grifols, from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the stock. Grifols, presently has an average rating of “Hold” and an average target price of $24.00.

Grifols, Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Institutional Ownership by Quarter for Grifols, (NASDAQ:GRFS)

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.